Anzeige
Meldung des Tages: Analyst sieht bei dieser Food-Tech-Aktie jetzt rund 100 % Kurspotenzial

Teva Pharmaceutical Aktie (ADR) News

Aktie
WKN:  883035 ISIN:  US8816242098 US-Symbol:  TEVA Branche:  Pharmazeutika Land:  Israel
31,81 $
+0,15 $
+0,47%
26,892 € 23.01.26
Depot/Watchlist
Marktkapitalisierung *
31,15 Mrd. €
Streubesitz
39,66%
KGV
-15,52
Dividende
0,071 €
Dividendenrendite
0,26%
Faktor
1
Originalaktie
IL0006290147
neu: Nachhaltigkeits-Score
58 %
Weiter aufwärts? Long handeln - Jetzt mit Hebel 9,16: UQ3RQ1
Werbung

Teva Pharmaceutical Aktie (ADR) News

20.10.25 - GlobeNewswire
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue ® , a biosimilar to Herceptin ® (trastuzumab) Tuznue ® received ...
10.10.25 - GlobeNewswire
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
FDA approves UZEDY ® (risperidone) extended-​release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the ...
25.09.25 - GlobeNewswire
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third ...
25.09.25 - GlobeNewswire
Teva Releases Q3 2025 Aide Memoire
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available ...
23.09.25 - dpa-AFX
Trump warnt Schwangere vor Paracetamol: Experte widerspricht
US-​Präsident Donald Trump hat schwangere Frauen wegen angeblicher Autismus-​Gefahr für ihre Kinder vor der Einnahme von Paracetamol gewarnt - Experten widersprechen ihm ...
21.09.25 - GlobeNewswire
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR ® (deutetrabenazine) extended-​release ...
21.09.25 - GlobeNewswire
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-​injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) ...
16.09.25 - GlobeNewswire
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed ...
09.09.25 - GlobeNewswire
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in ...
02.09.25 - GlobeNewswire
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September
TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and ...
29.08.25 - wallstreetONLINE Redaktion
Neues Abnehmmittel kommt!: Vorsicht Novo Nordisk & Eli Lilly - Teva bringt "Abnehm-Generika" auf US-Markt!
Novo Nordisk und Eli Lilly bekommen Konkurrenz: Teva steigt mit einem Generikum in den US-Markt für Abnehmpräparate ein. Mit der FDA-​Zulassung steigt der israelische ...
28.08.25 - GlobeNewswire
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
Generic Saxenda ® is the first-​ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market. This approval and ...
06.08.25 - GlobeNewswire
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
FDA approves single-​dose AJOVY ® (fremanezumab-​vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms ...
30.07.25 - GlobeNewswire
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy. Q2 2025 shows 10 th consecutive quarter of year-​over-year (YoY) revenue growth; Revenues ...
26.06.25 - GlobeNewswire
Teva Releases Q2 2025 Aide Memoire
TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on ...
26.06.25 - PR Newswire
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? PR Newswire
26.06.25 - PR Newswire
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? PR Newswire
25.06.25 - GlobeNewswire
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its ...
24.06.25 - GlobeNewswire
Abschließende Daten aus der realen PEARL-Studie von Teva untermauern die langfristige Wirksamkeit von AJOVY® (fremanezumab) für die Prävention chronischer und episodischer Migräne
Die abschließende Analyse der realen PEARL-​Studie für die Migräneprävention wurde auf dem 11. Kongress der European Academy of Neurology (EAN 2025) in Helsinki ...
23.06.25 - GlobeNewswire
Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine
Final analysis of PEARL real world migraine prevention study presented at 11th Congress of the European Academy of Neurology (EAN 2025) Congress in Helsinki 1 , 2 ...

Newssuche

Videos

newspaper
22.01.26 -5,56%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »
Anzeige

Aktie im Fokus

GOLD-AUSBRUCH
GMV Minerals
0,187 €
+13,3%
GMV Minerals Chart
Von der PEA zum Milliarden-Potenzial
Mehr zur Aktie »